Related Experiment Video
Updated: Feb 26, 2026
Optimized Protocol for Efficient Transfection of Dendritic Cells without Cell Maturation
Published on: July 8, 2011
Modifying Dendritic Cell Activation with Plasmonic Nano Vectors
Kieng Bao Vang1, Ingrid Safina2, Emilie Darrigues2
1Center for Integrative Nanotechnology Sciences, University of Arkansas at Little Rock, 2801 S University Avenue, Little Rock, AR, 72204, USA. kbvangdings@ualr.edu.
Abstract:
Dendritic cells (DCs) can acquire, process, and present antigens to T-cells to induce an immune response. For this reason, targeting cancer antigens to DCs in order to cause an immune response against cancer is an emerging area of nanomedicine that has the potential to redefine the way certain cancers are treated. The use of plasmonically active silver-coated gold nanorods (henceforth referred to as plasmonic nano vectors (PNVs)) as potential carriers for DC tumor vaccines has not been presented before. Effective carriers must be able to be phagocytized by DCs, present low toxicity, and induce the maturation of DCs-an early indication of an immune response. When we treated DCs with the PNVs, we found that the cell viability of DCs was unaffected, up to 200 μg/ml. Additionally, the PNVs associated with the DCs as they were phagocytized and they were found to reside within intracellular compartments such as endosomes. More importantly, the PNVs were able to induce expression of surface markers indicative of DC activation and maturation, i.e. CD40, CD86, and MHC class II. These results provide the first evidence that PNVs are promising carriers for DC-based vaccines and warrant further investigating for clinical use.
Insights
Plasmonic nano vectors (PNVs) show promise as carriers for dendritic cell (DC) vaccines. These PNVs are non-toxic, phagocytosed by DCs, and induce DC maturation for cancer immunotherapy.
Area of Science:
- Nanomedicine
- Immunology
- Biotechnology
Background:
- Dendritic cells (DCs) are crucial for initiating immune responses by presenting antigens to T-cells.
- Targeting cancer antigens to DCs is a promising nanomedicine strategy for cancer immunotherapy.
- The development of effective carriers for DC-based vaccines is essential for clinical translation.
Purpose of the Study:
- To investigate the potential of plasmonically active silver-coated gold nanorods (PNVs) as carriers for dendritic cell (DC) tumor vaccines.
- To evaluate the biocompatibility, cellular uptake, and immune-stimulating properties of PNVs in DCs.
Main Methods:
- DCs were treated with varying concentrations of PNVs.
- Cell viability was assessed using standard assays.
- Cellular association and intracellular localization of PNVs were examined.
- Expression of DC maturation markers (CD40, CD86, MHC class II) was analyzed via flow cytometry.
Main Results:
- PNVs demonstrated no significant toxicity to DCs up to 200 μg/ml.
- PNVs were efficiently phagocytosed by DCs and localized within endosomes.
- Treatment with PNVs significantly upregulated surface expression of CD40, CD86, and MHC class II on DCs.
Conclusions:
- PNVs are biocompatible and effectively taken up by DCs.
- PNVs induce DC maturation, indicating their potential as vaccine carriers.
- These findings support the further investigation of PNVs for clinical applications in DC-based cancer vaccines.
